Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Extension of Arikayce in Refractory MAC Lung Infection
NCT02628600Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Feb 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules, Lipid-based Nanoparticles
01
Overview
A Phase 3 trial of amikacin liposome inhalation suspension in Mycobacterium avium complex lung infection, sponsored by Insmed Incorporated. Started Feb 2016; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium avium complex lung infection
Beyond the preview
Go deeper on NCT02628600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628600.